About Us
Our Mission
Translyx Limited exists to introduce innovative diagnostic and clinical products to the New Zealand healthcare sector, supporting clinicians and health services with timely access to high-quality technologies that enable effective patient care.
Our highly experienced team brings decades of collective experience across diagnostics, laboratory medicine, clinical implementation, and healthcare supply. We focus on identifying globally validated clinical innovations and making them available to healthcare providers across hospital, community, and research settings. Our role is to bridge the gap between emerging clinical technologies and their practical use in everyday healthcare, with an emphasis on fit-for-purpose implementation, reliable supply, and strong local support.
Translyx takes a systems-based approach to product introduction, recognising that access to appropriate diagnostic and clinical tools plays an important role in supporting clinical decision-making and contributing to improved patient outcomes. The company works with healthcare organisations, laboratories, and academic partners to ensure innovative products are introduced in a way that aligns with real-world clinical needs.
Leadership
Dr Ehsan Ullah
Founding Director
Translyx Ltd was established in December 2025 by Dr Ehsan Ullah, an Auckland based physician scientist and healthcare entrepreneur advancing clinical diagnostic solutions in New Zealand.
Globally, the diagnostic market is undergoing rapid transformation driven by emerging trends in antimicrobial resistance (AMR), sepsis diagnostics, point of care testing, endocrinology, cardiac markers, Artificial intelligence, and precision medicine. These advances are reshaping clinical decision making and patient outcomes, creating a clear and urgent need for experienced leadership to bring advanced diagnostic technologies onshore to meet local healthcare demands. Dr Ullah brings an established professional profile at the intersection of clinical practice, laboratory medicine, and health technology innovation, including leadership roles across specialised diagnostics and digital health initiatives. His vision for Translyx is grounded in translating cutting edge global diagnostic innovations into practical and high impact solutions for the New Zealand healthcare system. The Translyx senior leadership team includes healthcare professionals with over 50 years of collective experience across the in vitro diagnostics (IVD) market, pathology services, and next generation molecular diagnostic solutions. The team is committed to building strategic partnerships and expanding access to high quality and clinically meaningful diagnostic tools. Translyx Ltd represents Dr Ullah's commitment to strengthening diagnostic capability in Aotearoa New Zealand, supporting clinicians, laboratories, and healthcare providers with advanced solutions that improve patient care and system resilience.
Operational Territory
Translyx operates primarily in New Zealand, with planned expansion into Australia and the broader Oceania region, including selected Pacific Island markets. The company works closely with local laboratories, hospitals, and healthcare providers to ensure diagnostic solutions are relevant, practical, and aligned with real clinical needs. Through regional partnerships and scalable distribution models, Translyx aims to strengthen diagnostic capability across Oceania while enabling efficient market access for international diagnostic innovators.